TN2009000249A1 - Mapk/erk kinase inhibitors - Google Patents

Mapk/erk kinase inhibitors

Info

Publication number: TN2009000249A1
Authority: TN; Tunisia
Prior art keywords: mapk; kinase inhibitors; erk kinase; compounds; methods
Prior art date: 2006-12-20

Application number

TNP2009000249A

Other languages

English (en)

Inventor

Qing Dong

Xianchang Gong

Stephen W Kaldor

Toufike Kanouni

Nicholas Scorah

Michael B Wallage

Feng Zhou

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-20

Filing date

2009-06-17

Publication date

2010-10-18

2009-06-17 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2010-10-18 Publication of TN2009000249A1 publication Critical patent/TN2009000249A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

TNP2009000249A 2006-12-20 2009-06-17 Mapk/erk kinase inhibitors TN2009000249A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87091306P	2006-12-20	2006-12-20
PCT/US2007/087913 WO2008079814A2 (fr)	2006-12-20	2007-12-18	Inhibiteurs de mapk/erk kinase

Publications (1)

Publication Number	Publication Date
TN2009000249A1 true TN2009000249A1 (en)	2010-10-18

Family

ID=39462025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000249A TN2009000249A1 (en)	2006-12-20	2009-06-17	Mapk/erk kinase inhibitors

Country Status (35)

Country	Link
US (4)	US8293901B2 (fr)
EP (1)	EP2125810B1 (fr)
JP (1)	JP5513127B2 (fr)
KR (1)	KR101488467B1 (fr)
CN (1)	CN101679411B (fr)
AR (1)	AR064640A1 (fr)
AU (1)	AU2007337003B2 (fr)
BR (1)	BRPI0720525B8 (fr)
CA (1)	CA2673647C (fr)
CL (1)	CL2007003742A1 (fr)
CO (1)	CO6230984A2 (fr)
CR (1)	CR10937A (fr)
DK (1)	DK2125810T3 (fr)
EA (1)	EA016312B1 (fr)
EC (1)	ECSP099529A (fr)
ES (1)	ES2430966T3 (fr)
GE (1)	GEP20125511B (fr)
HR (1)	HRP20130684T1 (fr)
IL (1)	IL199362A (fr)
JO (1)	JO2985B1 (fr)
MA (1)	MA31151B1 (fr)
MX (1)	MX2009006675A (fr)
MY (1)	MY157871A (fr)
NO (1)	NO342270B1 (fr)
NZ (1)	NZ578310A (fr)
PE (1)	PE20090071A1 (fr)
PL (1)	PL2125810T3 (fr)
PT (1)	PT2125810E (fr)
RS (1)	RS52887B (fr)
SI (1)	SI2125810T1 (fr)
TN (1)	TN2009000249A1 (fr)
TW (1)	TWI396538B (fr)
UA (1)	UA98479C2 (fr)
WO (1)	WO2008079814A2 (fr)
ZA (1)	ZA200904682B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1790649A1 (fr) *	2005-11-21	2007-05-30	Sanofi-Aventis	Dérivés de pyrimidone substitués bicycliques
TW200800997A (en) *	2006-03-22	2008-01-01	Astrazeneca Ab	Chemical compounds
ZA200903274B (en) *	2006-10-23	2010-08-25	Takeda Pharmaceutical	MAPK/ERK kinase inhibitors
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
SA08280783B1 (ar) *	2007-01-11	2011-04-24	استرازينيكا ايه بي	مشتقات بيريدوبيريميدين كمثبطات pde4
JP5363350B2 (ja) *	2007-03-19	2013-12-11	武田薬品工業株式会社	Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
CA2705452C (fr) *	2007-11-12	2016-05-31	Takeda Pharmaceutical Company Limited	Inhibiteurs de la mapk/erk kinase
WO2009146034A2 (fr) *	2008-03-31	2009-12-03	Takeda Pharmaceutical Company Limited	Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
CN102216274A (zh) *	2008-11-18	2011-10-12	武田药品工业株式会社	(R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
JP2013532627A (ja)	2010-07-01	2013-08-19	武田薬品工業株式会社	ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
TWI505828B (zh) *	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
TW201316991A (zh) *	2011-06-03	2013-05-01	Millennium Pharm Inc	Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
CA2866086C (fr)	2012-03-01	2020-06-09	Genentech, Inc.	Inhibiteurs de la serine / threonine kinase
JP2015511632A (ja) *	2012-03-30	2015-04-20	武田薬品工業株式会社	メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
JP6386177B2 (ja) *	2014-06-17	2018-09-05	ツーセンファーマシューティカルカンパニーリミテッド	ｍＴＯＲ／ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミジノン類似体
WO2016009306A1 (fr) *	2014-07-15	2016-01-21	Lupin Limited	Composés hétérocyclyles utilisés comme inhibiteurs de mek
KR101671404B1 (ko) *	2014-09-02	2016-11-02	한국원자력의학원	항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) *	2015-02-24	2016-09-01	学校法人兵庫医科大学	抗腫瘍効果増強剤および抗腫瘍剤
EP3643308B1 (fr) *	2017-06-23	2021-05-19	Cstone Pharmaceuticals	Composé de type coumarine tenant lieu d'inhibiteur de mek et ses applications
GB201713975D0 (en)	2017-08-31	2017-10-18	Macrophage Pharma Ltd	Medical use
US12378240B2 (en)	2018-11-20	2025-08-05	Nflection Therapeutics, Inc.	Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
JP2024047569A (ja) *	2022-09-26	2024-04-05	ファイザー・インク	Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
CN117779203B (zh) *	2024-02-28	2024-05-31	西北工业大学	一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5430148A (en)	1992-03-31	1995-07-04	Agouron Pharmaceuticals, Inc.	Antiproliferative quinazolines
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EA200100772A1 (ru)	1999-01-13	2002-02-28	Варнер-Ламберт Компани	Бензогетероциклы и их применение в качестве мек ингибиторов
YU50402A (sh)	2000-01-25	2005-11-28	Warner-Lambert Company	Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
AP2001002217A0 (fr)	2000-07-19	2001-09-30	Warner Lambert Co	Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
DK1333833T3 (da)	2000-10-23	2011-12-12	Glaxosmithkline Llc	Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
US6825180B2 (en)	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
SI2130537T1 (sl)	2002-03-13	2013-01-31	Array Biopharma, Inc.	N3-alkilirani derivati benzimidazola kot inhibitorji mek
CA2478534A1 (fr)	2002-03-13	2003-09-25	Array Biopharma, Inc.	Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek
ATE411992T1 (de) *	2003-05-23	2008-11-15	Fterna Zentaris Gmbh	Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2005002351A2 (fr)	2003-07-03	2005-01-13	Sunghag Koo	Huile de ginseng fermentee
DE602004023207D1 (de)	2003-07-24	2009-10-29	Warner Lambert Co	Benzimidazol-derivate als mek-hemmer
WO2005011597A2 (fr)	2003-07-29	2005-02-10	Irm Llc	Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
DK1682138T3 (da)	2003-11-19	2011-04-18	Array Biopharma Inc	Heterocykliske inhibitorer af MEK
US7378423B2 (en)	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
HRP20080018T3 (en) *	2004-06-11	2008-01-31	Japan Tobacco	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
DE102004054215A1 (de)	2004-11-10	2006-05-11	Merck Patent Gmbh	Pyridopyrimidinonderivate
AU2005311451A1 (en)	2004-12-01	2006-06-08	Merck Serono Sa	[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
CA2657287A1 (fr)	2006-07-17	2008-01-24	Merck & Co., Inc.	Composes de 1-hydroxy naphtyridine en tant qu'agents anti-vih
ZA200903274B (en) *	2006-10-23	2010-08-25	Takeda Pharmaceutical	MAPK/ERK kinase inhibitors
WO2008055842A1 (fr)	2006-11-09	2008-05-15	F. Hoffmann-La Roche Ag	Dérivés de 6-phényl-pyrido [2,3-d] pyrimidine-7-one substitués utilisés comme inhibiteurs de la kinase et méthodes d'utilisation de ceux-ci
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
CA2705452C (fr) *	2007-11-12	2016-05-31	Takeda Pharmaceutical Company Limited	Inhibiteurs de la mapk/erk kinase
WO2009146034A2 (fr) *	2008-03-31	2009-12-03	Takeda Pharmaceutical Company Limited	Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
CN102216274A (zh) *	2008-11-18	2011-10-12	武田药品工业株式会社	(R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法

2007
- 2007-12-17 JO JOP/2007/0555A patent/JO2985B1/ar active
- 2007-12-18 UA UAA200907471A patent/UA98479C2/ru unknown
- 2007-12-18 US US12/520,247 patent/US8293901B2/en active Active
- 2007-12-18 NZ NZ578310A patent/NZ578310A/en unknown
- 2007-12-18 HR HRP20130684TT patent/HRP20130684T1/hr unknown
- 2007-12-18 GE GEAP200711376A patent/GEP20125511B/en unknown
- 2007-12-18 BR BRPI0720525A patent/BRPI0720525B8/pt active IP Right Grant
- 2007-12-18 CA CA2673647A patent/CA2673647C/fr active Active
- 2007-12-18 WO PCT/US2007/087913 patent/WO2008079814A2/fr not_active Ceased
- 2007-12-18 JP JP2009543137A patent/JP5513127B2/ja active Active
- 2007-12-18 ZA ZA200904682A patent/ZA200904682B/xx unknown
- 2007-12-18 ES ES07869422T patent/ES2430966T3/es active Active
- 2007-12-18 KR KR20097015218A patent/KR101488467B1/ko active Active
- 2007-12-18 AU AU2007337003A patent/AU2007337003B2/en active Active
- 2007-12-18 MX MX2009006675A patent/MX2009006675A/es active IP Right Grant
- 2007-12-18 MY MYPI20092545A patent/MY157871A/en unknown
- 2007-12-18 RS RS20130315A patent/RS52887B/sr unknown
- 2007-12-18 DK DK07869422.1T patent/DK2125810T3/da active
- 2007-12-18 SI SI200731281T patent/SI2125810T1/sl unknown
- 2007-12-18 PT PT78694221T patent/PT2125810E/pt unknown
- 2007-12-18 US US11/958,999 patent/US8030317B2/en active Active
- 2007-12-18 CN CN2007800503244A patent/CN101679411B/zh active Active
- 2007-12-18 EA EA200970605A patent/EA016312B1/ru unknown
- 2007-12-18 PL PL07869422T patent/PL2125810T3/pl unknown
- 2007-12-18 EP EP07869422.1A patent/EP2125810B1/fr active Active
- 2007-12-20 AR ARP070105806A patent/AR064640A1/es active IP Right Grant
- 2007-12-20 TW TW096149026A patent/TWI396538B/zh active
- 2007-12-20 CL CL200703742A patent/CL2007003742A1/es unknown
2008
- 2008-01-02 PE PE2008000065A patent/PE20090071A1/es active IP Right Grant
2009
- 2009-06-15 IL IL199362A patent/IL199362A/en active IP Right Grant
- 2009-06-17 TN TNP2009000249A patent/TN2009000249A1/fr unknown
- 2009-07-10 MA MA32088A patent/MA31151B1/fr unknown
- 2009-07-15 NO NO20092692A patent/NO342270B1/no unknown
- 2009-07-17 CO CO09074721A patent/CO6230984A2/es active IP Right Grant
- 2009-07-17 CR CR10937A patent/CR10937A/es unknown
- 2009-07-21 EC EC2009009529A patent/ECSP099529A/es unknown
2010
- 2010-10-07 US US12/900,350 patent/US20110065733A1/en not_active Abandoned
2012
- 2012-04-18 US US13/450,064 patent/US8470837B2/en active Active

Also Published As

Publication number	Publication date
ZA200904682B (en)	2010-09-29
DK2125810T3 (da)	2013-07-29
BRPI0720525A2 (pt)	2014-01-07
NZ578310A (en)	2012-01-12
KR101488467B1 (ko)	2015-01-30
BRPI0720525B1 (pt)	2020-03-03
NO20092692L (no)	2009-09-16
GEP20125511B (en)	2012-05-10
TWI396538B (zh)	2013-05-21
CR10937A (es)	2009-11-20
HRP20130684T1 (en)	2013-10-11
MY157871A (en)	2016-07-29
AU2007337003A1 (en)	2008-07-03
CA2673647C (fr)	2016-02-09
JP5513127B2 (ja)	2014-06-04
JO2985B1 (ar)	2016-09-05
AU2007337003A2 (en)	2009-07-30
PE20090071A1 (es)	2009-04-04
CO6230984A2 (es)	2010-12-20
SI2125810T1 (sl)	2013-09-30
WO2008079814A2 (fr)	2008-07-03
BRPI0720525B8 (pt)	2021-05-25
US20110065733A1 (en)	2011-03-17
MX2009006675A (es)	2009-08-12
US8470837B2 (en)	2013-06-25
EA016312B1 (ru)	2012-04-30
IL199362A (en)	2013-07-31
PL2125810T3 (pl)	2013-09-30
RS52887B (sr)	2014-02-28
TW200835496A (en)	2008-09-01
MA31151B1 (fr)	2010-02-01
EA200970605A1 (ru)	2009-12-30
ECSP099529A (es)	2009-08-28
CA2673647A1 (fr)	2008-07-03
WO2008079814A3 (fr)	2008-09-04
PT2125810E (pt)	2013-07-29
US8030317B2 (en)	2011-10-04
US20080255160A1 (en)	2008-10-16
NO342270B1 (no)	2018-04-30
JP2010514680A (ja)	2010-05-06
CL2007003742A1 (es)	2008-06-13
KR20090091353A (ko)	2009-08-27
CN101679411B (zh)	2013-04-17
US8293901B2 (en)	2012-10-23
US20100130518A1 (en)	2010-05-27
UA98479C2 (en)	2012-05-25
AR064640A1 (es)	2009-04-15
CN101679411A (zh)	2010-03-24
EP2125810A2 (fr)	2009-12-02
US20120202999A1 (en)	2012-08-09
ES2430966T3 (es)	2013-11-22
EP2125810B1 (fr)	2013-04-24
AU2007337003B2 (en)	2013-05-02

Publication	Publication Date	Title
TN2009000249A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
WO2008115890A3 (fr)	2009-04-30	Inhibiteurs de mapk/erk kinase
WO2009146034A3 (fr)	2010-07-15	Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
TN2010000131A1 (en)	2011-09-26	Polo-like kinase inhibitors
WO2008079787A8 (fr)	2009-07-16	Activateurs de glucokinase
MY150542A (en)	2014-01-30	Cmet inhibitors
WO2007117995A3 (fr)	2008-01-10	Inhibiteurs de kinase
WO2007104034A3 (fr)	2008-02-28	Activateurs de la glucokinase
WO2008116107A3 (fr)	2009-03-19	Activateurs de glucokinase
MY146989A (en)	2012-10-15	Kinase inhibitors
ATE479687T1 (de)	2010-09-15	Kinaseinhibitoren
WO2010008847A3 (fr)	2010-10-21	Inhibiteurs de pi3k/m tor
WO2008055236A3 (fr)	2008-10-09	Inhibiteurs de kinase mapk/erk
MX339476B (es)	2016-05-27	Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PT2470546E (pt)	2013-10-14	Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2007143434A3 (fr)	2008-07-03	Activateurs de glucokinase
MX2010012298A (es)	2011-03-15	Activadores de glucocinasa.
TN2009000151A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
WO2010111626A3 (fr)	2010-11-18	Inhibiteurs de la poly(adp-ribose)polymérase (parp)
TN2011000207A1 (en)	2012-12-17	Akt and p70 s6 kinase inhibitors
WO2008054956A3 (fr)	2008-09-04	Inhibiteurs de kinases
WO2009129401A8 (fr)	2009-12-17	Inhibiteurs de kinases
WO2008045834A3 (fr)	2008-07-24	Inhibiteurs de kinases
WO2008089005A3 (fr)	2009-01-15	Inhibiteurs de rénine
TN2009000130A1 (en)	2010-10-18	Kinase inhibitors